Clinical trials: Stage II Prostate Adenocarcinoma
Prostate Cancer
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
This is a study to test the safety and efficacy of an investigational chemotherapy agent in patients with advanced prostate cancer.
- Trial name
- NCT00780975
- Testing
- Aplidin (plitidepsin)
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- PharmaMar
Pain, Prostate Cancer
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00005960
- Testing
- filgrastim, cyclophosphamide, docetaxel
- Where
- 6 sites in United States
- Sponsor
- Amgen
Advanced Solid Tumor, Cholangiocarcinoma
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors (solid tumor, BTC and…
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer
- Trial name
- NCT05253053
- Testing
- TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
- Where
- 9 sites in China
- Volunteers
- 84 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Prostatic Neoplasms
G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
A single-arm, open-label Phase II clinical trial to evaluate the effect of G-202 on the perfusion and volume of the prostate using non-invasive multiparametric prostate magnetic resonance imaging (mpMRI).
- Trial name
- NCT02381236
- Testing
- G-202
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- GenSpera, Inc.
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Prostate Cancer
PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
PROSTVAC-VF is an investigational cancer vaccine. The vaccine is based on the theory that the immune system can be taught to fight cancer by directing the immune system to attack specific targets found on cancer cells.
- Trial name
- NCT00078585
- Testing
- PROSTVAC®-VF/TRICOM™
- Where
- 47 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bavarian Nordic
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
A Phase I/II study of an in-situ therapeutic cancer vaccine. Vaccines contain a source of antigen and and adjuvant. In this study the source of tumor antigen comes from the killing of a selected tumor by cryoablation (killing…
- Conditions
- Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT01065441
- Testing
- AlloStim, Cryoablation
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Michael Har-Noy
Prostate Cancer
Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with G-CSF may make tumor cells more sensitive to the chemotherapy drug and may kill…
- Trial name
- NCT00003183
- Testing
- filgrastim, mitoxantrone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Hope Cancer Institute, Inc.
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621.
- Trial name
- ACTIVATED-4-PC (NCT07192614)
- Testing
- AZD6621
- Where
- 26 sites in United States, Belgium and 7 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Prostate Cancer, Adenocarcinoma
A Long Term Safety Study With Atrasentan
The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.
- Trial name
- NCT00127478
- Testing
- Atrasentan
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 166 people
- Sponsor
- Abbott
Prostate Cancer
CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. CT-2584 may stop the growth of prostate cancer by stopping blood flow to the tumor.
- Trial name
- NCT00004026
- Testing
- CT-2584, chemotherapy
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- CTI BioPharma
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Prostatic Neoplasms
Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate Cancer
This study involves the use of an experimental product, TG4010. The purpose of the study is to determine if TG4010 can stimulate the body's immune system to help it fight the cancer.
- Trial name
- NCT00040170
- Testing
- MVA-MUC1-IL2
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Transgene
Prostate Cancer, Prostate Adenocarcinoma
Trilostane for Androgen-Independent Prostate Cancer
The main purpose of this study is to test the safety of trilostane by looking at what effects, good and bad, it has on patients with androgen-independent prostate cancer.
- Trial name
- NCT00181597
- Testing
- Trilostane, Hydrocortisone
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genzyme, a Sanofi Company
Prostate Cancer
Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
This Phase II single dose study was designed to characterize the safety, tolerability, and efficacy of intravenous (i.v.) panobinostat as a single-agent treatment in participants with hormone refractory prostate cancer.
- Trial name
- NCT00667862
- Testing
- Panobinostat
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer
RATIONALE: Pomegranate extract may keep prostate cancer from growing in patients with rising prostate-specific antigen (PSA) levels after surgery or radiation therapy for localized prostate cancer.
- Trial name
- NCT00336934
- Testing
- pomegranate juice
- Volunteers
- 183 people
- Sponsor
- Roll International Corporation
Prostate Cancer
DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic…
- Trial name
- NCT00024414
- Testing
- DHA-paclitaxel
- Where
- 8 sites in United States
- Sponsor
- Theradex